Computer modeling, genomics, and prostate cancer prognosis

A newly published paper on the development of prostate cancer in patients of ≤ 55 years of age claims to have shown that

Using a newly-developed computer model, it is now possible to predict the course of the disease in individual patients. … READ MORE …

Commercially available liquid biopsy data may be misleading

A newly published research letter in JAMA Oncology is entitled “Patient-paired sample congruence between 2 commercial liquid biopsy tests”. The two tests are both said — by the companies that market them — to have high clinical sensitivity and specificity in the identification of specific genetic markers associated with high-risk forms of prostate cancer. … READ MORE …

Artificial intelligence and the personalization of cancer therapy

It appears that the ability of Watson to revolutionize the treatment of cancer and provide personalized information that would substantially improve the management of cancer for individual patients may have been over-hyped (click here).

Planning out personalized therapy for metastatic prostate cancer

A new paper from researchers at the University of Santa Cruz and UCLA, just published in the journal Cell, has laid out the beginnings of a method to identify personalizable forms of therapy for men with metastatic forms of prostate cancer. … READ MORE …

The value in personalization of expectant management strategies

A recent and truly excellent review in Nature Reviews: Urology offers us a very thoughtful set of insights on the role of “expectant” and “conservative” management (i.e., active surveillance and watchful waiting) in the care of men with prostate cancer today. … READ MORE …

Are you a good candidate for the TAPUR study? If so, sign up!

Nearly a year ago now, the American Society of Clinical Oncology (ASCO) first announced plans to initiate an innovative trial of a personalized medicine initiative called the Targeted Agent and Profiling Utilization Registry (TAPUR) study. … READ MORE …

A small subgroup of patients with mCRPC responds to carboplatin + everolimus

There is an increasing level of evidence about our ability to identify small and carefully selected groups of patients with advanced disease who, despite the fact that they no longer respond to standard treatments, may respond well to other forms of therapy. … READ MORE …